

# Marc R Mansour

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/878194/publications.pdf>

Version: 2024-02-01

46  
papers

4,324  
citations

279798

23  
h-index

289244

40  
g-index

46  
all docs

46  
docs citations

46  
times ranked

7421  
citing authors

#	ARTICLE	IF	CITATIONS
1	Therapeutic targeting of "undruggable" MYC. <i>EBioMedicine</i> , 2022, 75, 103756.	6.1	136
2	Anti-CCR9 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2022, 140, 25-37.	1.4	29
3	Current and emerging therapeutic approaches for T-cell acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2021, 194, 28-43.	2.5	16
4	Prognostic value of Oncogenetic mutations in pediatric T Acute Lymphoblastic Leukemia: a comparison of UKALL2003 and FRALLE2000T protocols. <i>Leukemia</i> , 2021, , .	7.2	2
5	Synergistic melanoma cell death mediated by inhibition of both MCL1 and BCL2 in high-risk tumors driven by NF1/PTEN loss. <i>Oncogene</i> , 2021, 40, 5718-5729.	5.9	1
6	CD1a is rarely expressed in pediatric or adult relapsed/refractory T-ALL: implications for immunotherapy. <i>Blood Advances</i> , 2020, 4, 4665-4668.	5.2	11
7	EZH2-Deficient T-cell Acute Lymphoblastic Leukemia Is Sensitized to CHK1 Inhibition through Enhanced Replication Stress. <i>Cancer Discovery</i> , 2020, 10, 998-1017.	9.4	29
8	Targeting cytokine- and therapy-induced PIM1 activation in preclinical models of T-cell acute lymphoblastic leukemia and lymphoma. <i>Blood</i> , 2020, 135, 1685-1695.	1.4	28
9	Successful remission induction therapy with gilteritinib in a patient with <i>de novo</i> FLT3-mutated acute myeloid leukaemia and severe COVID-19. <i>British Journal of Haematology</i> , 2020, 190, e189-e191.	2.5	17
10	In <i>trans</i> early mosaic mutational escape and novel phenotypic features of germline SAMD9 mutation. <i>British Journal of Haematology</i> , 2020, 188, e53-e57.	2.5	6
11	Disruption of <i>asxl1</i> results in myeloproliferative neoplasms in zebrafish. <i>DMM Disease Models and Mechanisms</i> , 2019, 12, .	2.4	18
12	The role of noncoding mutations in blood cancers. <i>DMM Disease Models and Mechanisms</i> , 2019, 12, .	2.4	9
13	Prognostic impact of the absence of biallelic deletion at the <i>TRG</i> locus for pediatric patients with T-cell acute lymphoblastic leukemia treated on the Medical Research Council UK Acute Lymphoblastic Leukemia 2003 trial. <i>Haematologica</i> , 2018, 103, e288-e292.	3.5	5
14	JDP2: An oncogenic bZIP transcription factor in T cell acute lymphoblastic leukemia. <i>Journal of Experimental Medicine</i> , 2018, 215, 1929-1945.	8.5	22
15	Activation of the LMO2 oncogene through a somatically acquired neomorphic promoter in T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2017, 129, 3221-3226.	1.4	61
16	Small genomic insertions form enhancers that misregulate oncogenes. <i>Nature Communications</i> , 2017, 8, 14385.	12.8	76
17	TOX Regulates Growth, DNA Repair, and Genomic Instability in T-cell Acute Lymphoblastic Leukemia. <i>Cancer Discovery</i> , 2017, 7, 1336-1353.	9.4	48
18	Synergy between loss of NF1 and overexpression of MYCN in neuroblastoma is mediated by the GAP-related domain. <i>ELife</i> , 2016, 5, .	6.0	29

#	ARTICLE	IF	CITATIONS
19	Chromosomal Translocations and Gene Rearrangements in Acute Lymphoblastic Leukaemia. , 2015, , 189-222.		0
20	Targeting oncogenic interleukin-7 receptor signalling with N-acetylcysteine in T cell acute lymphoblastic leukaemia. British Journal of Haematology, 2015, 168, 230-238.	2.5	20
21	A Zebrafish Model of Myelodysplastic Syndrome Produced through CRISPR Genomic Editing. Molecular and Cellular Biology, 2015, 35, 789-804.	2.3	58
22	Notch signaling: switching an oncogene to a tumor suppressor. Blood, 2014, 123, 2451-2459.	1.4	225
23	Cyclin C is a haploinsufficient tumour suppressor. Nature Cell Biology, 2014, 16, 1080-1091.	10.3	124
24	An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. Science, 2014, 346, 1373-1377.	12.6	665
25	Ribonucleoprotein HNRNPA2B1 Interacts With and Regulates Oncogenic KRAS in Pancreatic Ductal Adenocarcinoma Cells. Gastroenterology, 2014, 147, 882-892.e8.	1.3	56
26	Novel activating mutations lacking cysteine in type I cytokine receptors in acute lymphoblastic leukemia. Blood, 2014, 124, 106-110.	1.4	50
27	SMN2 Selective Inhibitor of Nuclear Export (SINE), Selinexor (KPT-330), Shows Remarkable Activity Against AML Leukemia-Initiating Cells. Blood, 2014, 124, 995-995.	1.4	0
28	KPT-330 inhibitor of CRM1-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia. British Journal of Haematology, 2013, 161, 117-127.	2.5	149
29	The TAL1 complex targets the FBXW7 tumor suppressor by activating miR-223 in human T cell acute lymphoblastic leukemia. Journal of Experimental Medicine, 2013, 210, 1545-1557.	8.5	107
30	HSP90 Inhibition Has Potent Activity Against T-Cell Acute Lymphoblastic Leukemia (T-ALL) Through Degradation Of TYK2 Kinase. Blood, 2013, 122, 2528-2528.	1.4	0
31	Targeting Oncogenic Interleukin-7 Receptor Signaling With N-Acetylcysteine In T-Cell Acute Lymphoblastic Leukemia. Blood, 2013, 122, 2535-2535.	1.4	0
32	A Genetic Screen In Zebrafish Identified Dlst As a Potential Therapeutic Target For Human Acute T-Lymphoblastic Leukemia. Blood, 2013, 122, 1273-1273.	1.4	0
33	The TAL1 Complex Represses the FBXW7 Tumor Suppressor Through Mir-223 in Human T-Cell Acute Lymphoblastic Leukemia. Blood, 2012, 120, 1296-1296.	1.4	0
34	Discovery of a Secreted Tumor Suppressor Provides a Promising Therapeutic Strategy for Follicular Lymphoma. Cancer Cell, 2011, 20, 559-561.	16.8	3
35	Pten mediates Myc oncogene dependence in a conditional zebrafish model of T cell acute lymphoblastic leukemia. Journal of Experimental Medicine, 2011, 208, 1595-1603.	8.5	104
36	Pten mediates Myc oncogene dependence in a conditional zebrafish model of T cell acute lymphoblastic leukemia. Journal of Cell Biology, 2011, 194, i4-i4.	5.2	1

#	ARTICLE	IF	CITATIONS
37	Prognostic Implications of <i>NOTCH1</i> and <i>FBXW7</i> Mutations in Adults With T-Cell Acute Lymphoblastic Leukemia Treated on the MRC UKALLXII/ECOG E2993 Protocol. <i>Journal of Clinical Oncology</i> , 2009, 27, 4352-4356.	1.6	108
38	Oncogenic Kras and Notch-1 cooperate in T-cell acute lymphoblastic leukemia/lymphoma. <i>Expert Review of Hematology</i> , 2009, 2, 133-136.	2.2	2
39	T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). <i>Blood</i> , 2009, 114, 5136-5145.	1.4	346
40	Structure of the Notch1-negative regulatory region: implications for normal activation and pathogenic signaling in T-ALL. <i>Blood</i> , 2009, 113, 4381-4390.	1.4	154
41	WT1 mutations in T-ALL. <i>Blood</i> , 2009, 114, 1038-1045.	1.4	111
42	Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. <i>Journal of Clinical Investigation</i> , 2008, 118, 3143-3150.	8.2	1,069
43	Notch-1 Mutations Are Secondary Events in Some Patients with T-Cell Acute Lymphoblastic Leukemia. <i>Clinical Cancer Research</i> , 2007, 13, 6964-6969.	7.0	70
44	Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. <i>Nature</i> , 2007, 447, 966-971.	27.8	355
45	A role for aberrant Notch signaling in acute myeloid leukemia?. <i>Leukemia and Lymphoma</i> , 2006, 47, 2280-2281.	1.3	1
46	High Incidence of Notch-1 Mutations in Adult Patients with T-Cell Acute Lymphoblastic Leukaemia.. <i>Blood</i> , 2005, 106, 1447-1447.	1.4	3